Product Description
ASTX-030 is being developed by Astex for the treatment of patients with Myelodysplastic Syndrome. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04608110?term=ASTX-030&draw=2&rank=2)
Mechanisms of Action: DNA Mtase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Otsuka
Company Location:
Company Founding Year: 1921
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Czech Republic, France, Germany, Hungary, Italy, Japan, Poland, Spain, United Kingdom, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Anemia, Refractory, with Excess of Blasts|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04256317 |
AZTOUND Study | P3 |
Recruiting |
Acute Monocytic Leukemia|Myelodysplastic Syndrome|Anemia, Refractory, with Excess of Blasts|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia |
2027-11-01 |
21% |
2026-03-19 |
Primary Endpoints |
NCT04608110 |
NCT04608110 | P1 |
Recruiting |
Myelodysplastic Syndrome |
2027-12-01 |
12% |
2026-08-11 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
jRCT2021200025 |
jRCT2021200025 | P1 |
Recruiting |
Myelodysplastic Syndrome |
1970-01-01 |
|||
2024-515098-93-00 |
ASTX030-01 | P3 |
Not yet recruiting |
Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia |
2027-11-15 |